NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) posted its quarterly earnings data on Wednesday, October, 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.07 by $0.06. The medical research company had revenue of $717.60 million for the quarter, compared to the consensus estimate of $729.63 million. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The business's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.88 EPS. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences issued an update on its FY18 earnings guidance on Wednesday, October, 31st. The company provided earnings per share (EPS) guidance of $4.22-4.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.19. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.91 billion.PRA Health Sciences also updated its FY 2018 guidance to $4.22-4.27 EPS.

8 Wall Street analysts have issued 12 month price objectives for PRA Health Sciences' shares. Their predictions range from $100.00 to $120.00. On average, they expect PRA Health Sciences' stock price to reach $113.50 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

News coverage about PRAH stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PRA Health Sciences earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Senomyx (SNMX).

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.12%), Scout Investments Inc. (0.10%), Navellier & Associates Inc (0.08%), Gateway Investment Advisers LLC (0.03%), Louisiana State Employees Retirement System (0.02%) and KAMES CAPITAL plc (0.02%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Scout Investments Inc., KAMES CAPITAL plc, Fox Run Management L.L.C., Oakbrook Investments LLC, Louisiana State Employees Retirement System and CENTRAL TRUST Co. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Highland Capital Management LLC, Meeder Asset Management Inc., Advisors Capital Management LLC, Retirement Systems of Alabama, Navellier & Associates Inc and State of Alaska Department of Revenue. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $101.65.

PRA Health Sciences has a market capitalization of $6.60 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

The official website for PRA Health Sciences is http://www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]